Does Human Specimen Research Always Need Consent?
4:50 minutes
Should scientists be allowed to study your biological specimens — such as blood, urine or tissue samples — if you haven’t expressly given them permission?Bioethicist Holly Fernandez Lynch explains why researchers worry that the requirement for consent could bias research, slow research progress, and endanger patient privacy.
What if the samples were left over from a doctor’s visit or a different study that you did consent to, and stripped of information that would identify you?
According to proposed updates to ethics rules imposed by the US government, the answer to both questions is almost always no. Many advocate that you should be required to give explicit consent for the use of your specimens, especially as new medical developments are making it possible to link once-anonymous samples back to their donors.
However, under current rules, researchers can use human biological specimens leftover from blood drawn at the doctor’s office or leftover from previous research. But the US government is proposing an update to those rules.
“What’s being proposed to be changed now is saying, ‘It doesn’t matter if those specimens have been de-identified. We’re still going to require researchers to get your consent before using them,’” saysHolly Fernandez Lynch, the executive director of the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard Law School.
Patient advocates support the proposed consent requirement, or even say it doesn’t go far enough in offering patients privacy or control over how their medical information is used.
“The good … in proposing this rule change is people don’t know how their specimens are being used and if we fail to tell them, we’re going to lose trust in the research enterprise,” Lynch says. “We really ought to be telling people what we’re doing with their specimen — so that’s sort of the justification that’s been put forth.”
But not everyone thinks the new rules are a good idea. The National Academies of Science, Engineering and Medicine released a report last week arguing that the update is so ill-conceived that the government should start over, this time with an independent commission crafting the rules.
“What the government is proposing to require is not specific, informed consent,” Lynch says. “Every time your samples get used over again, instead, what they’re proposing is broad consent at the time the specimen is collected so that you would say to the patient, ‘OK, we’ve collected this specimen. Whenever there’s something left over we’re going to give it to researchers and they can do what they want with it now.’
“That’s not really so protective of individual autonomy, right? Because you don’t know, as the patient, exactly, how your specimens are going to be used. … For people who think consent is important, the broad consent that’s been proposed doesn’t go far enough,” Lynch says.
Not only do people argue the consent doesn’t do what it’s supposed to do, many researchers say the ill-conceived rules would make future studies more difficult and expensive.
“Requiring consent in this way can actually be quite damaging. … There’ll be all sorts of logistical concerns for institutions … and what may end up happening is that the institutions that are more poorly resourced are not going to ask consent. Instead they’re just going to say ‘Forget it. We’re not going to make those samples available for research.’ And that can end up biasing the samples that become available for research purposes going forward,” Lynch says.
There is, however, a possible way forward, according to Lynch.
“One of the things that we recommended was public education about how specimens are being used,” Lynch says. “It makes a lot of sense that people are confused. We think that there’s a responsibility for researchers and institutions to explain the value of biospecimen research — how low risk it is — and help people, you know, become aware of the social benefit of this research.”
“One thing short of requiring actual consent would be an option to opt out of having your specimens be used if you’re opposed to it. And then the last thing to do would be to punish people who are nefariously re-identifying specimens. That’s something that’s not currently part of the regulations or law and it would be an important protection to add.”
Segment Guests
Holly Fernandez Lynch
Holly Fernandez Lynch is the Executive Director of the Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard Law School in Cambridge, Massachusetts.
Segment Transcript
IRA FLATOW: And now it’s time to play good thing, bad thing.
[MUSIC PLAYING]
Because every story has a flip side. Should scientists have to ask for permission to study blood samples you gave at the doctor’s office, or for a different study you already consented to years ago? Right now, they don’t have to. But the Obama administration is proposing some new rules for how scientific research treats human subjects and these kinds of secondary uses of biospecimens.
And under the proposed rules, researchers would have to get consent every time they re-used your samples. What do scientists think? A report by the National Academies of Science, Engineering, and Medicine is calling for the administration to scrap the proposal entirely and start over. Why would scientists be against more consent? Here with some insight is my guest Holly Fernandez Lynch, executive director of the Petri Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School. Welcome to Science Friday.
HOLLY FERNANDEZ LYNCH: Thank you for having me.
IRA FLATOW: So what exactly is the rule change the government is proposing?
HOLLY FERNANDEZ LYNCH: So just as you explained, when there are leftover specimens– left over from blood drawn at the doctor’s office, or leftover from research that you participated in previously– as long as those specimens don’t have any identifiers about you still attached to them, researchers are currently allowed to use them for whatever purposes they would like, without going back to you to get your consent. And what’s being proposed to be changed now, is saying it doesn’t matter if those specimens have been de-identified. We’re still going to require researchers to get your consent before using them.
IRA FLATOW: I just wanted to know– so what’s the good and the bad about this?
HOLLY FERNANDEZ LYNCH: So the good– what the government has said in proposing this rule change is, well, people don’t know how their specimens are being used. And if we fail to tell them, we’re going to lose trust in the research enterprise. And trust is really important for the cancer moonshot and the Precision Medicine Initiative. And so we really ought to be telling people what we’re doing with their specimens. So that’s sort of the justification that’s been put forth.
The bad is a couple of things, in my view. One, what the government is proposing to require is not specific informed consent every time your samples get used over again. Instead what they’re proposing is broad consent at the time the specimen is collected, so that you would say to the patient, OK, we’ve collected this specimen. Whenever there’s something left over, we’re going to give it to researchers and they can do what they want with it.
Now that’s not really so protective of individual autonomy, right? Because you don’t know, as the patient, exactly how your specimens are going to be used. And so it doesn’t– for people who think consent is important, the broad consent that’s been proposed doesn’t go far enough. The other problem with it from the scientist’s perspective is that requiring consent in this way can actually be quite damaging to biospecimen research going forward, because it’s not that easy to collect consent and track it going forward. It’s going to be quite expensive to do that. There will be all sorts of logistical concerns for institutions and for research institutions. And what may end up happening, is that the institutions that are more poorly resourced are not going to ask consent. Instead they’re just going to say forget it. We’re not going to make those samples available for research. And that can end up biasing the samples that become available for research purposes going forward.
IRA FLATOW: Is there a middle ground somewhere– something that you might suggest?
HOLLY FERNANDEZ LYNCH: There is. So I actually sit on a government advisory panel. I’m not speaking on their behalf. But one of the things that we recommended was public education about how specimens are being used. It makes a lot of sense that people are confused. We’re not telling them about this. And so we think that there’s a responsibility for researchers and institutions to explain the value of biospecimen research, how low risk it is, and help people become aware of the social benefit of this research. That’s one thing. Another step–
IRA FLATOW: I’ve got about 30 seconds. So–
HOLLY FERNANDEZ LYNCH: Yeah. Short of requiring actual consent would be an option to opt out of having your specimens be used, if you’re opposed to it. And then the last thing to do would be to punish people who are nefariously re-identifying specimens. That’s something that’s not currently part of the regulations or laws. And it would be an important protection to add.
IRA FLATOW: Thank you very much. Holly Fernandez Lynch is at the Harvard Law School of Bio of Biotechnology and Bioethics.
Copyright © 2016 Science Friday Initiative. All rights reserved. Science Friday transcripts are produced on a tight deadline by 3Play Media. Fidelity to the original aired/published audio or video file might vary, and text might be updated or amended in the future. For the authoritative record of ScienceFriday’s programming, please visit the original aired/published recording. For terms of use and more information, visit our policies pages at http://www.sciencefriday.com/about/policies.
Meet the Producer
About Christie Taylor
@ctaylsaurusChristie Taylor was a producer for Science Friday. Her days involved diligent research, too many phone calls for an introvert, and asking scientists if they have any audio of that narwhal heartbeat.